Form 4: Aquestive Therapeutics Director Marco Taglietti Acquires Stock Options

Director Marco Taglietti acquired stock options for 38,000 shares of Aquestive Therapeutics common stock on June 20, 2024.

Summary

• Marco Taglietti, a director of Aquestive Therapeutics, Inc., acquired stock options on June 20, 2024.
• The options grant the right to purchase 38,000 shares of common stock at an exercise price of $2.50.
• The options vest on June 20, 2025, contingent upon Dr. Taglietti's continued service with the company.
• The options expire on June 20, 2034.

Sentiment

Score: 6

Explanation: The document indicates a standard stock option grant to a director, suggesting a neutral to slightly positive sentiment as it reflects continued alignment of interests.

Positives

• The acquisition of stock options by a director signals confidence in the company's future performance.

Industry Context

Stock option grants are a common practice for incentivizing company directors and aligning their interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants to directors are a standard component of executive compensation packages in the pharmaceutical industry.
• The vesting schedule of one year is fairly typical for such grants.

Stakeholder Impact

• The stock option grant aligns the director's interests with those of shareholders, potentially encouraging decisions that increase shareholder value.

Key Dates